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1 Introduction and review of the literature 
Central nervous system tumours require special knowledge in routine 
pathological workout, and for this reason in many neuro-oncological centres 
specialized neuropathologists are employed. Meningioma is a tumour 
frequently encountered in standard neuropathological practice. In most cases, 
diagnosis of these tumours is not problematic, although there are challenging 
cases, too. In affluent countries complementary molecular studies can also be 
helpful and are often available as part of routine work-up. However, in Hungary, 
the routine use of such techniques is currently far from reality; neither financial 
nor technical conditions are available. 
The aim of this study is to establish an easy-to-use immunohistochemical 
(IHC) panel from the currently available reagents in pathological institutes for 
routine neuropathological use, which can predict meningioma 
relapse/recurrence, and can help with the questionable cases. For validation we 
analysed the changes in immunohistochemical characteristics and expression 
patterns during relapse/recurrence and examined their relation to tumour grade. 
In our work, we investigated proteins using conventional 
immunohistochemical methods that can assist in the determination of 
meningiomas and can provide evidence for prognosis with regards to 
relapse/recurrence. It is also important in the recurrence of individual cases to 
establish what changes the second tumours went through, how they evolved; 
therefore we studied how proteins change in different samples of the same 
patient. We selected proteins which through DNA repair can significantly 
influence the development of tumours such as poly(ADP-ribose) polymerase 
(PARP1); and on the other hand, they are significant in preserving genome 
integrity and have been shown to be involved in many tumours (p53); and also 
manifest in the active phase of cell division (Ki-67, Mib1 antibody). We also 
studied the widely analysed progesterone receptor (PR), which is known to be 
inversely related to grade, but less is currently known about its relationship to 
recurrence. 
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1.1. Meningiomas 
Meningiomas are meningothelial cell originated tumours that typically stick 
to the inner surface of the dura mater. Generally they are benign, although rarely 
poor prognosis may occur. 
Meningiomas are one of the most common intracranial tumours, usually 
sporadic, but may also be familiar. Their incidence increases with age, are found 
most commonly in ages 60 to 70; and they show mild female predominance 
(1.7: 1). Meningiomas account for almost 24-30% of intracranial tumours. Their 
annual incidence is about 13/100000 inhabitants. 
Meningiomas are typically slow-growing tumours. Depending on 
localization and size they may be clinically completely asymptomatic, but may 
cause focal pressure symptoms and consequent neurological deficits, diplopia, 
headaches or epileptic episodes. Meningiomas on the MRI are typically 
isodense, uniform contrast material enhancing nodules, which usually adhere to 
the dura mater. Possible calcification can be usefully investigated with CT scan 
and contrast material can be used to further clarify the diagnosis. 
The ethology of meningiomas is not fully understood. But full skull 
irradiation is a well-known risk factor, specifically for irradiation involving 
scalps and survivors of nuclear bombs. The effects of sex hormones are even 
less clear. However, the fact that they predominant in women, and in the 
overweight, endogenous/exogenous hormone intake, smoking, and oestrogen, 
progesterone and androgen hormone positivity support a possible connection. 
Meningiomas were one of the first solid tumours in which cytogenetic 
abnormalities were described, such as monosomy or deletion of the long arm of 
chromosome 22. The deletion, insertion or nonsense mutation of 
Neurofibromatosis 2 gene on the 22 chromosome is found in 60% of sporadic 
meningiomas. In addition, epigenetic differences may play a role in their 
development (promoter hyper methylation, histone modification, micro-RNAs). 
Meningiomas may be intracranial, intraspinal or orbital in localisation. In 
the skull most of them are located on the convex plane or parasagittal. 
Intraspinal meningiomas are most commonly found in the thoracic region. The 
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metastases of anaplastic meningiomas are mainly found in the bones, the lungs, 
the pleura and the liver. 
Macroscopically meningiomas are rubbery firm, well-demarcated, 
sometimes lobulated, rounded nodules. Invasion of the related dura and dural 
sinuses may occur. In advanced cases, through the dura mater they can infiltrate 
to the skull bones. The surrounding brain often shows an impression, but 
cerebral invasion is rare, they usually grow microscopically around the brain 
vessels, but true intravascular infiltration is rare. Meningiomas with 
immunohistochemical examinations are generally positive for EMA, Vimentin 
and S100, but EMA in higher gradations is weak or less pronounced. The many 
tissue variants of meningiomas also determine their WHO grade. The definition 
of the grade is based on the 2007 WHO Classification of Tumours of the Central 
Nervous System: histopathologic subtype, morphological appearance and 
increased mitotic activity. 
Meningothelial meningioma (WHO grade I.): a common classical variant 
in which tumour cells form lobules, with a thin collagen septum. Tumour cells 
are uniform with oval nuclei, and a fine chromatin structure, in which pseudo-
inclusions may appear. Within the lobe, tumour cells can grow in a syncytium-
like fashion because the cellular projections form fine, complex forms which 
cannot always be differentiated by light microscopy. 
Fibroblastic meningioma (WHO grade I.): a subtype which shows spindle-
shaped cells that form parallel bundles in the collagen-rich extracellular matrix, 
with a focally typical appearance of a meningothelial meningioma. 
Transitional meningioma (WHO grade I.): the mixed appearance of 
meningothelial and fibroblastic subtypes. 
Other WHO grade I. subtypes: angiomatous meningioma, psammomatous 
meningioma, lympho-plasmocyte rich meningioma, metaplastic meningioma, 
microcytic meningioma and secretory meningioma. 
Atypical meningioma (WHO grade II.): meningiomas belonging to this 
group have increased mitotic activity (more than 4/10 high power field, hpf), 
brain invasion, or at least 3 of the following characteristics: increased 
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cellularity; small cells with a large nucleus:cytoplasmic ratio; a prominent 
nucleus; a patternless growth pattern; focal or "map-like" necrosis. Tumours 
that meet these criteria are eight times more likely to recur than the WHO grade 
I. meningiomas. 
Other WHO grade II. meningiomas: chordoid meningioma and clear cell 
meningioma. 
Anaplastic meningioma (WHO grade III.): in these cases the tumour 
expresses a malignant tissue pattern similar to the tissue appearance of 
carcinoma, melanoma, or high-grade sarcoma. It is characterized by a high 
mitotic division (more than 20/10 hpf), high Mib1 labelling index and extensive 
necrosis. These tumours are highly aggressive, with an average survival of 2-5 
years. 
Other WHO grade III. meningiomas: papillary meningioma and rhabdoid 
meningioma. 
In 2016, the WHO revised the 2007 classification for central nervous 
system tumours, including meningiomas: cerebral invasion may occur in benign 
and aggressive tumours, and the rate of relapse equals atypical tumours. At 
present, the behaviour of the tumour is indicated by clinical factors and tissue 
parameters. In the case of brain invasion, tumour cells form irregular, tongue-
like projections in the brain, with reactive astrocytosis. Extracranial metastases 
are extremely rare (1/1000 meningioma). 
The rate of recurrence is different in each of the grades: 7-25% in WHO 
grade I., 30-50% in the WHO grade II. And 50-95% WHO grade III. For 
meningiomas, both progression-free survival and overall survival are closely 
related to WHO grade. In routine diagnostic practice, we need one or more 
"atypical" or "malignant" markers; and we need markers to determine the high 
chances of relapses/recurrences. The p53, the PARP1, the Mib1 or the PR may 
be such candidate. 
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1.2. PARP protein family 
The PARP (Poly(ADP-ribose) polymerase) protein family consists of 17 
members, their main function is single-stranded DNA repair and participating 
in programmed cell death. If a DNS error is detected, the DNS binding domain 
is attached to the defective DNS thereby causing a conformational change in the 
protein. To connect to the programmed cell death, the caspase cleavage domain 
is required. 
PARP1 (also known as ADP-ribosyltransferase D-type 1, ARTD1) is 
responsible for about 90% of PARP activity, and is a 116 kDa protein found in 
the nucleus. Its gene is located on the long arm of chromosome 1 (1q42.12). It 
can be activated by exogenous and endogenous genotoxic effects, such as 
chemical (oxygen and nitrogen free radicals), physical (radius, heat) or 
metabolic (hypoxia, increased extracellular glucose concentration, hormone, 
steroid) factors. The activated enzyme binds to DNA and produces Poly (ADP-
ribose) (PAR). PAR activates other proteins (DNA ligase III, DNA polymerase 
beta, XRCC1) and the base excision repair is started. Subsequently, the polymer 
is disrupted by the PARG. Activated PARP1 is capable of reacting with other 
nuclear enzymes by PARylating them, thereby increasing their negative charge, 
preventing interaction with other anionic molecules, like the DNA. In addition 
to the DNA correction function, activated PARP1 plays an important role in 
apoptosis by activating the 'caspase' pathway, causing the apoptotis-inducing 
factor to migrate from the mitochondria to the nucleus. However, in case of 
severe DNA damage, ATP deficiency can cause necrosis. In addition, PARP1 
'knock out' cells decrease single strand breaks, the DNA replication villa stops 
and double strand breaks are recovered by homologous recombination. For this 
reason, PARP1 deficient cells exhibit hyper-recombination phenotypes. 
Previous studies have shown that PARP1 plays a role in BRCA1 / BRCA2 
mutant breast tumours. PARP inhibitors are capable of enhancing the effect of 
chemotherapeutics by inhibiting single strand DNA repair, while repairing 
double strand DNA fractures has also been impaired due to BRCA mutation. 
The role of PARP1 has been studied in many solid tumours but, as far as we 
know nobody has investigated them in meningiomas. 
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1.3. p53 protein 
p53 is a 43.7 kDa weight protein. Its different homologues are important 
proteins in all multicellular organisms, by inhibiting the formation of tumours. 
p53 coded by the TP53 gene can be found on the short arm of 17 chromosomes 
(17p13.1), and is one of the most important tumour-suppressor proteins in 
humans. The physiological function of p53 is to regulate the cell cycle, preserve 
the stability of the genome, and prevent mutations. p53 may be activated by 
DNA damage, oxidative stress, osmotic shock, ultraviolet light, ionizing 
radiation, ribonucleotide depletion or oncogene expression. Activation causes a 
significant increase in the half-life and changes the conformation of the protein. 
Normally, Mdm2 is responsible for the low level of p53: it blocks the function 
and is also responsible for its degradation. 
The anti-tumour activity of p53 can be accomplished in different ways: it 
activates DNA repair enzymes; creates a cell proliferative barrier at the G1/S 
regulatory site, thereby providing sufficient time for the repairing enzymes to 
correct the DNA defect; and it can induce apoptosis if the DNS damage is 
irreversible. TP53 is the most common mutant gene in human tumours 
(detectable in 50%, with a recessive trait). p53 resulting from genetic 
modification can be demonstrated by immunohistochemical methods, which 
correlates well with the mutation status. However, in the case of elevated p53 
levels in physiological conditions, a false positive result can be obtained. In 
congenital p53 mutations (Li-Fraumeni syndrome), they often develop tumours 
in early adulthood (sarcoma, breast tumours, glioblastoma, adrenal tumours, 
hematologic tumours). 
The role of p53 has been previously studied in meningioma: many studies 
yielded negative or uncertain results, while others found significant correlations 
between p53 status and tumour grade or recurrence. 
There have been numerous publications about the relationship between 
PARP1 and p53, and how PARP1 regulates the function of p53 both directly 
and indirectly via the polymers and the promoter of MTA1. 
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1.4. Progesterone receptor 
Progesterone receptor (PR) is a steroid receptor. PR is encoded by the PGR gene 
located on the long arm of 11 chromosomes (11q22). PR has two isoforms: PR-
A and PR-B, which are identical except for the 165-amino acid portion of the 
PR-B 'N terminal, which has the function of transcription activation. 
When the progesterone hormone binds to its receptor, it undergoes dimerization 
and transports to the nucleus where it binds to DNA and induces transcription. 
The resulting mRNA migrates into ribosomes to trigger protein-specific 
translation. PR’s physiological role lies in the maintenance of female hormonal 
cycle regulation, ovulation, pregnancy, and breast tissue development during 
puberty. The progesterone hormone plays a role in breast carcinogenesis. 
Synthetic progesterone analogues and prolonged ovarian activity increase the 
chance of breast cancer, but bilateral ovarian removal can also reduce breast 
cancer risk by 50%. 
It is known that meningiomas are positive for anti-PR antibodies and that the 
proportion of positive cells is inversely proportional with the WHO grade, 
which can help in determining the grade in questionable cases. Previous 
research has also revealed that the PR cellular biosynthesis is not an oestrogen-
controlled process in meningiomas, as in other sex hormone dependent tissues; 
only some cases are oestrogen positive. 
 
1.5. Ki-67 protein, Mib1 antibody 
The Ki-67 is a nuclear-based protein, which is encoded by the MKI67 gene 
located on the 10th chromosome (10q25-ter). The 395 kDa and 345 kDa weight 
Ki-67 is a huge protein of two isoforms encoded by 30,000 base pairs in the 
human genome. Its exact function is still unknown. We know that the Ki-67 
protein is essential for cell division; it can be found in all the active phases of 
the cell cycle (G1, S, G2, M), but cannot be detected in G0 phase cells. In 
addition, Ki-67 is essential for ribosomal RNA transcription. During the 
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interphase it is only found in the nucleus, but during mitosis the protein binds 
to the surface of the chromosomes. During the mitosis the protein has 
phosphorylation and dephosphorisation. Some researchers presume that the Ki-
67 protein is involved in the organization of DNA. While others belive that it is 
binds to SNA or RNA, forming complexes with other proteins, however, Ki-67 
participate in the synthesis of ribosomes during cell division. 
Mib1 (Molecular Immunology Borstel 1) as a proliferative marker is the most 
commonly used monoclonal anti-Ki-67 antibody. The Mib1 antibody can be 
used on formalin fixed and paraffin embedded samples after pre-microwave 
treatment or heat-induced antigen recovery. In routine pathological workup 
Mib1 is particularly important in cases of lymphomas, melanocytic tumours and 
cervical intraepithelial neoplasia, in determining the dysplasia in ulcerative 
colitis and the differentiation of basaloid carcinoma from basal cell hyperplasia 
in prostate. The Mib1 labelling index (Li) has a strong correlation with tumour 
growth rate, chances of relapse/recurrence and survival, i.e. prognosis of 
hematologic and solid tumour types, including meningioma. Some authors have 
found that p53 positivity and high proliferative index also indicate a worse 
clinical behaviour even in benign tissue histology. It is now also known that the 
proportion of proliferative fraction is inversely related to relapses/recurrences. 
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2. Material and methods 
During routine pathological processing, after at least 24 hours but no more 
than 168 hours in 10% buffered formalin fixation the macroscopic descriptions 
of specimens were made. The portions of the lesions for microscopic 
examination were put in plastic cassettes. This was followed by the dehydration 
phase of the samples, on the automatic Shandon Pathcentre Tissue Processor 
(Thermo Fisher Scientific Waltham, Massachusetts, USA). 
The dehydrated tissue samples were embedded in paraffin, producing 
'paraffin blocks'. From these, 4μm thick sections were made using “wheeled 
microtome” (Leica RM2245 - Semi-Motorized Rotary Microtome, Leica 
Biosystems, Wetzlar, Germany) on silanized slides, followed by hematoxylin-
eosin staining (H&E) in automated and standardized conditions using the Leica 
ST 5020 (Leica Biosystems, Wetzlar, Germany) automatic machine. 
Histopathological reports from H&E stained sections were stored in the medical 
database of MedSolution (T-systems Hungary Ltd., Debrecen Support Centre) 
and in the archives of the institute. 
The samples required for our retrospective investigations were searched in 
the MedSolution database. The FFPE blocks of the selected cases were found in 
the institute archive. All cases were re-screened by a neuropathologist, 
classified into histological subtypes and relevant WHO grading according to the 
2007 WHO Classification of Tumours of the Central Nervous System. 
Immunohistochemistry investigations were always carried out under 
automated and standardized conditions. 4 μm sections were made from FFPE 
sections. Manual method was used for detecting antigen retrieval and antibody 
dilution. Next we used the automated Leica Bond Max ™ immunohistochemical 
machine with the Bond ™ Polymer Refine Detection Kit on the samples. The 
immunohistochemical reaction was always performed according to the 
manufacturer's protocol under standardized conditions, with negative controls. 
The 4 micrometre sections were labelled with PARP1 polyclonal rabbit 
antibody, p53 monoclonal mouse antibody, progesterone receptor monoclonal 
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antibody, and monoclonal anti-Ki67 antibody. Antibodies were diluted 1: 500 
for PARP1, 1: 100 for p53, 1: 100 for PR and 1: 200 for Mib1. 
 
Our investigations were carried out in two rounds. 
 
2.1 First experiment round  
Firstly we performed PARP1 and p53 immunohistochemical reactions on 
a small patient group: 41 samples of 31 patients with meningioma. 100 
randomly selected cells were counted in 10 fields of view at 400X 
magnification. We measured the intensity of the labelling as negative (0+), 
weak (1+), medium (2+), or strong (3+) nuclear staining. 
On the basis of the staining we calculated two parameters (staining 
intensity, Si): ratio of 1+, 2+ and 3 + cells (Si1-3), and the ratio of highly stained 
2+ and 3+ cells (Si2- 3) relative to all the counted cells. 
The results were analysed with SPSS 19.0 for Windows statistical software. 
Since the samples did not show normal distribution, we used nonparametric 
statistical tests. The Kruskall-Wallis H test can be used to compare 3 or more 
different groups; the Mann-Whitney U test is suitable for comparing two non-
normal distribution groups. By means of these statistical tests, we investigated 
whether the given samples could originate from the same population. Where the 
significance level was sufficiently low (<0.5; <0.1; <0.01) we were able to state 
that the samples were from different populations; that is they were statistically 
different. The non-parametric Spearman's rank order correlation test also 
reveals whether the relationship between the two parameters can be described 
with a monotonic function (for each X there is only one Y value in the 
coordinate system and vice versa). If so, it can be said that changing one value 
can be determined by changing the other value; that is the changes are related 
to one another. 
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First for both proteins (p53 and PARP1) we tested with Kruskall-Wallis H 
tests both Si1-3 and Si2-3 according to the three WHO grades. Then we 
compared the individual WHO grades (WHO grade I.-II., I.-III. and II.-III.) with 
Mann-Withney U test. Two groups were then made on the basis of the WHO 
grade: low-grade (WHO grade I.) and high-grade (WHO grade II. and III.) and 
these values were compared with Mann-Whitney U test. Spearman's rank order 
correlation test was performed to determine the independence of the 
immunohistochemical labelling of PARP1 and p53 proteins. 
 
2.2 Second experiment round 
As a second step, we performed studies on a larger patient group, with a 
total of 114 surgical specimens from 70 patients. Samples were selected 
retrospectively within a 16-year interval. Patients with one or more 
relapses/recurrences were classified in the R/R group. The patients in the non-
R/R group had no relapsed/recurrent tumour detected by radiological studies or 
during autopsy. 
By selecting one or two representative blocks from each case, TMA (tissue 
micro array) was constructed from cylinders of the most typical areas based on 
the morphology of the particular tissue sample. Each TMA contained 10 
recipient blocks of samples: 3-3 cylinders per sample; and 2 marker cylinders. 
Thus, a total of 12 TMAs were built, which included all 114 specimens. 
Hematoxylin & eosin (H&E) staining and immunohistochemical (IHC) 
reactions were performed on these TMAs. 
Each H&E and IHC section was digitized on the Pannoramic Scanner. 
From each of the digital samples six images were extracted (2-2 from each 
cylinder cross-section) on 400x magnification. Based on the intensity of the 
positive nuclei, 4 groups were created: 0, 1+, 2+ and 3+. 
In many cases, in the beginning of our studies we calculated the number and 
ratio of positively staining cells (labelling index, Li) exactly, with the Cell 
Counter function of the ImageJ program, and later we used these as templates 
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for comparison. By multiplying the ratio and strength of staining cells, 
Histoscore was assigned also to each histological sample. 
Results were analysed using the SPSS 22.0 for Windows statistical program. 
As samples were not normal, we used non-parametric tests: Kruskall-Wallis H 
test, Mann-Whitney U test, and Wilcoxon signed rank test. The Wilcoxon signed 
rank test is a non-parametric equivalent of the two-sample t test for examining 
interrelated patterns. Using this method we studied the changes in the different 
surgical samples from the same patient. 
The number of ethics license: DEOEC RKEB: 2437-2005 
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3. Results 
3.1 Results of the first experiment round 
All examined 41 samples showed positivity for PARP1 and p53 antibody.  
Kruskall-Wallis H test showed significant correlation between the WHO grade 
and the PARP1 expression (Si1-3, p=0.001) as well as p53 intensive labelling 
(Si2-3, p=0.012). In contrast, there was no statistically significant correlation 
between Si2-3 PARP1 (p=0.523), Si1-3 p53 (p=0.141) staining and the WHO 
grade. 
With Mann-Whitney U test PARP1, Si1-3 showed a significant correlation 
with WHO grade I.-II. (p=0.001) and WHO grade II-III. (p= 0.005). In addition, 
in the case of p53, Si2-3 showed a significant association with WHO grade I-
III. (p=0.002). The peak intensity was shown by the WHO grade II. tumours for 
the PARP1, whereas peak intensity was shown by theWHO grade III. for the 
p53. 
Comparisons of low grade tumours (WHO grade I.) and the high grade 
tumours (WHO grade II. and III.) showed a significant correlation Si1-3 
(p=0.028) in the case of PARP1, while there was significant correlation for Si2-
3 (p=0.018) with the p53 staining. The histopathological subgroup of tumours 
was as follows:  WHO grade I.: 11 meningothelial, 8 transitional, 1 secretory, 1 
fibroblastic and 1 microcytic; WHO grade II.: 8 atypical and 3 clear cell; WHO 
grade III.: all of them were anaplastic. There was no significant difference 
between the individual histological subtypes, neither for PARP1 nor p53. 
Spearman's rank order correlation study showed no relationship between 
PARP1 and p53 immunoassay. 
 
3.2. Results of the second experiment round 
There were 16 patients (3 men, 13 women; mean age 54 years) who had not 
had a relapse or recurrence of their tumours at least 5 years after their first 
operation (non-R/R group). In 31 patients (8 men, 23 women, mean age 53 
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years, average recurrence time 19.6 months), tumour recurrence was confirmed 
by imaging or pathological studies (R/R group). There were 23 patients (5 
males, 18 female, mean age 59 years) who had had a single operation due to 
meningeal tumour less than 5 years prior to the end of our studies and no 
relapses had been confirmed. However, due to the short time window, these 
patients were excluded from non-R/R group. 
Of the examined samples, 65 were classified as WHO grade I., 33 as WHO 
grade II. and 16 as WHO grade III. All non-R/R cases belonged to WHO grade 
I. The R/R group contained 19 WHO grade I., 9 WHO grade II. and 3 WHO 
grade III. during the neuropathological study from the first operation. Eight of 
these patients showed progression in their grade and 15 showed the same grade 
in both the first and last specimen. Six patients in the R/R group had only one 
histological sample. In their cases, the relapse was verified by the imaging test 
without tissue sampling. There were no significant differences in the tissue 
subtypes among the groups: 6 meningothelial, 5 transitional, 3 fibroblastic and 
2 psammomatous in the non-R/R group; whereas 9 meningothelial, 6 
transitional, 3 fibroblastic, 1 psammomatous, 1 clear cell, 8 atypical and 3 
anaplastic were found in the R/R group. No particular tissue subtype of WHO 
grade I tumours was onstanding in terms of relapse/recurrence, nor was any 
histological subtype from WHO grades II. and III. recorded as outstanding 
(Noting that the test sample count was low for each subtype). 
The individual WHO grades compared with Kruskall-Wallis H test showed 
significant correlation with the Mib1 percentage, intensity and Histoscore; p53 
intensity and Histoscore; PR percentage, intensity, and Histoscore. When 
compared by Mann-Whitney U test WHO grade I. and II. showed a significant 
correlation with the Mib1 percentage, intensity and Histoscore; p53 intensity; 
PR percentage, intensity, and Histoscore. Comparison between the WHO grade 
II. and WHO grade III. indicate significant differences between the p53 
intensity; the PR percentage, intensity and Histoscore. Among the WHO grade 
I. and WHO grade III. we found significant correlation between the percentage 
of Mib1 and Histoscore; p53 intensity and Histoscore; PR percentage, intensity, 
and Histoscore. 
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During the comparison of R/R and non-R/R groups a significant correlation 
between Mib1 percentage, intensity and Histoscore; p53 percentage and the 
WHO grade was found. However, when we compared the WHO grade I. 
members of the R/R group to the non-R/R group (each case was WHO grade 
I.), it was found that there was a significant correlation between the percentage 
of Mib1, Histoscore; p53 percentage and Histoscore. 
Finally, we compared the first and last histological samples from the R/R group: 
there was a significant correlation between the Mib1 percentage, Histoscore; 
p53 intensity and WHO grades. With Wilcoxon signed rank test comparison of 
the first and last histological samples of each patient showed a significant 
differences between the WHO grades, Mib1 percentage Histoscore; and p53 
percentage. 
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4. Discussion 
As one of the most common intracranial tumours, meningioma has many 
morphological variants. According to the current (2016) WHO classification, 
13 histological variants can be distinguished. Nine of them are among the WHO 
grade I., 2 belong to the WHO grade II. and 2 to the WHO grade III. The atypical 
and anaplastic can be diagnosed on the basis well defined morphological criteria 
(tissue appearance, mitosis number, brain invasion), although this is sometimes 
difficult. Until now, there has been no reliable immunohistochemical marker 
that could help to differentiate between the WHO grades. However, it is true 
that the Simpsons (surgical) grade can help in judging the chances of recurrence. 
Meningiomas are essentially non-infiltrating tumours, so surgical removal is 
generally curative. However, small tumour nests may appear along the dura 
mater, which may be a source of recurrence. Since chemotherapy is not effective 
in such cases, and radiotherapy increases the chance of malignant 
transformation, this is another pressing argument for finding simple markers 
that help assess the tumour progression and recurrence. Today's imaging studies 
provide a number of valuable information to assist the surgeon's work 
(localization, relationship to anatomical sites, vascularity, oedema), but also 
prognostic aspects: dural tail, and possible existing tumour nests along the dura. 
At present, the meningeal patient management at the University of Debrecen, 
in line with the international guidelines, contains a follow up: after a 
postoperative imaging study - for possible residual tumour examination – MRI 
examination in every six months for one year, and every year for four years to 
detect possible relapse. If there is no diagnostic recurrence, they will be treated 
as healed. 
During our studies we conducted a retrospective analysis of the 
neurosurgically acquired histological samples from patients diagnosed with 
meningioma in the course of the last 16 years at the Department of Pathology, 
Faculty of Medicine, University of Debrecen. The available samples were 
classified according to the 2007 WHO recommendation. In the course of our 
investigations, two proteins involved in DNA repair and the preservation of 
genome integrity were investigated; the PARP and p53, respectively. The 
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relationship of these proteins with the WHO grade was also investigated. In 
addition, we analysed recurrent meningeal cases and sought protein markers 
from routine pathological practice such as Ki-67, progesterone receptor, p53, 
which could assist in judgement about the chance of recurrence. 
PARP1, the most important and most widely studied protein from the PARP 
family has a well-known and important role in caspase independent apoptotic 
pathway and necrotic cell death. PARP1 has been studied in several tumours: 
breast cancer, ovarian, endometrial, pancreatic tumours, stomach tumours, 
certain colorectal malignancies, germinal tumours, prostate carcinomas, 
melanoma, Ewing's sarcoma, neuroblastomas, glioblastomas; but as far as we 
know no one has investigated its role in meningiomas. 
p53 is one of the most important tumour suppressor proteins, it is significant 
in about half of the human malignancies. Numerous studies have been 
conducted on the p53 marker in meningiomas, but they have yielded varying 
results; some of them had a negative result and others showed a correlation 
between p53 status and WHO grade or event of recurrences. 
All 41 samples tested in the first round showed positivity for both PARP1 
and p53 antibodies. For PARP1, the ratio of positive cells (Si1-3) was the 
highest in the WHO grade II. tumour; in the case of p53, the positivity (Si2-3) 
showed a gradual increase and WHO grade III. tumours proved to be the 
highest. Compared to the low-grade (WHO grade I.) and high-grade (WHO 
grades II. and III.) meningiomas, higher Si1-3 was found for PARP1, while the 
Si2-3 value was higher for p53 in the high-grade cases. Spearman's rank order 
correlation test and linear regression analysis showed no correlation between 
PARP1 and p53 labelling, confirming that these two markers are not dependant 
to each other. 
We assume that PARP1 activation increases in the WHO grade II. tumours 
can occur because the cells are trying to cope with DNA defects, while in the 
WHO grade III. tumours the PARP1 activity decrease may be due to 
apoptotic/necrotic cell death and lack of protein substrates. According to our 
results, the p53 protein plays a role in meningiomas, and this is likely to be a 
late occurrence of meningioma’s tumour progression. Based on our experience, 
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the presence of p53 protein showed a steady increase and the highest values 
were found in the WHO grade III. group. Interestingly, for PARP1, the 
significant correlation was seen in the ratio of any labelling cells (Si1-3), while 
in the case of p53 only in the proportion of intensive 2+ and 3+ cells (Si2-3). 
We assume that the reason for this is that while the PARP1 protein is practically 
no detectable in intact dura cells, the wild type of p53, which is also labelled 
with the antibody, can produce a weak reaction (1+). This also confirms our 
hypothesis that the more intense mutant p53 is related to the tumour grade and 
is not affected by the potential physiological accumulation of the wild-type 
protein. Since both proteins showed higher markers in the examination of 'high 
grade' (WHO grade II. and III) tumours, the role of both proteins can be assumed 
in cases of worse prognosis. Although further studies are required, our findings 
have shown that PARP1 and p53 may help to diagnose and determine the WHO 
grade in meningiomas. 
In the second part of our research we were looking for an easy-to-use 
immunohistochemical panel for everyday neuropathological practice which 
could help to determine the likelihood of relapse/recurrences of meningiomas. 
This could be a great help with problematic localisation (such as falx cerebri) 
tumours. 
The labelling index of the Mib1 marker may be different in each laboratory, 
but in standardized conditions it may help in comparing cases both for scientific 
and routine diagnostic testing. Earlier studies have shown that higher initial 
Mib1 labelling indexes more aggressive behaviour, faster growth, increased 
recurrence tendency, worse prognosis, and is inversely proportional to 
recurrence-free time in many tumour types, including meningiomas. In our 
studies, we have found that the Mib1 ratio and Histoscore increase with the 
WHO grade. In recurrent cases, higher Mib1 values were observed. These 
values were not only detected in the examination of all WHO grade tumours, 
but also in cases of only WHO grade I. meningiomas. Accordingly, tumours 
which are classified as WHO grade I. (but do not have the criteria for WHO 
grade II.) and have elevated Mib1, are more likely to show recurrence. In 
addition a consistent Mib1 index increase has been found during the course of 
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recurrent cases, which coincides with tumour progression and higher 
proliferation of high WHO grade tumours. 
For p53, higher values were also observed in higher WHO grades. 
However, it was interesting to note that a higher ratio of p53 was detected in 
non-recurrent cases. This is probably due to the fact that the p53 antibody used 
in the clinical routine (and in our studies) does not distinguish between the wild 
type and the mutant protein. It is assumed that, in non-recurrence cases, the 
elevated normal p53 level is advantageously effective in repairing DNA 
damage. In contrast, in higher cases, the presence of mutant p53 has been 
shown, which is ineffective, thus contributing to tumour growth. Mutation 
analysis may answer this question, but it was outside the scope of our analysis; 
we focused on identifying immunohistochemical markers that could be used in 
a daily clinical practice. The intensity of the p53 protein could be seen to 
increase through the course of samples from the same patient with recurrent 
disease, and this may be due to the selective overgrosth of cells with mutant p53 
protein. 
Similarly to our results, previous studies have also reported that 
progesterone receptor expression is inversely proportional to WHO grade in 
meningiomas, which can assist in the determination of the WHO grade. In line 
with our results, other researchers have also found that although PR 
immunostaining is proportional to the WHO grade, it does not help to determine 
the probability of relapses/recurrences. In our studies there was no significant 
correlation with PR in relation to recurrence, and there were no differences in 
the presence of different tumours from the same patient. As these tumours have 
a hormone receptor, this raises the possibility of hormone therapy, thus the 
determination of a progesterone receptor may have therapeutic potential. 
 
Briefly summarised: 
 There is a significant correlation between the detection of tumour markers 
(PARP1, p53, Mib1 and PR) and meningioma groups based on the 
behaviour. 
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 The presence and changes of PARP1 and p53 are independent of each 
other. 
 PARP1, p53 and Mib1 grow directly proportionally to the WHO grade. 
 PR is inversely proportional to WHO grade. 
 By comparing the histological slides of R/R and non-R/R patients of all 
WHO grades: we could confirm the previous research finding that the 
Mib1 index and the expression of the p53 proteins both indicate and predict 
the aggressive tumour behaviour. 
 Examining the behaviour and immunohistochemical characteristics of 
WHO grade I. meningiomas only: Mib1 clearly predicts a higher 
probability of relapses/recurrences - while in p53 this relationship does not 
exist or even inverts (this may be explained by the difference in function 
of the wild and mutant protein variant). 
 Comparing samples from patients in case of recurrence we found that the 
WHO grade, Mib1 percentage, Histoscore, and p53 percentage show 
significant differences and increase overtime 
Our results in the near future could be further enhanced by digital image 
analysis and automation, because these methods provide standardised results 
that are nowadays used by researchers in common practice. In the near future, 
they could become part of everyday routine pathologic work. 
In conclusion, we constructed a simple immunohistochemical panel that 
can be used for daily work to help diagnose, determine the grade, and predict 
the highly-recurrent meningioma cases, which need a tighter follow-up 
protocol. 
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5. Summary 
Meningiomas are one of the most frequent intracranial tumours and occur 
in high numbers in neuropathological practice. Although these tumours are 
usually benign, recurrences may occur. According to WHO criteria there are 3 
grades, indicating increasing tumour aggressiveness. There are cases where the 
WHO grading is difficult, therefore we need immunohistochemical markers to 
help distinguished such cases. The DNA damage repair protein PARP1, p53 as 
’the guardian of the genom’, the intranuclear progesterone receptor, and the 
proliferation marker Mib1 (anti-Ki67 antibody) are possible candidates. 
Our experiments were carried out in two phases: first on a small group of 
patients’ samples (41 samples of 31 patients) and later on more patients (114 
samples of 70 patients). We applied automated immunohistochemical methods, 
which are routinely used at the Institute of Pathology, University of Debrecen 
Clinical Centre. In the second round we performed the study on samples built 
into a tissue microarray (TMA) paraffin block. The samples were digitalised 
and the staining percentage, average staining intensity, and Histoscore 
(multiplying the above two readouts) were calculated. The samples were 
grouped according to WHO grades, and the relapse/recurrence (presence or 
absence) within a five-year interval was calculated and analysed with statistical 
tests (Kruskall-Wallis H, Mann-Whitney U, Wilcoxon signed rank test, 
Spearman’s rank order correlation). 
Our results revealed a correlation between WHO grade and PARP1, p53, 
Mib1 and PR expression, respectively. PARP1 has the highest value in WHO 
Grade II meningiomas, whereas p53 shows the highest value in WHO Grade III 
tumours. The expression of PARP1 and p53 are not related to each other. 
PARP1, p53 and Mib1 show direct proportion, while the PR shows inverse 
proportion to the WHO Grade. Regarding relapse/recurrence, only the Mib1 and 
p53 show differences. 
Our findings could help the diagnostic neuropathological work-up of 
meningiomas, and provide information for clinicians regarding the likelihood 
of tumour relapse/recurrence.  
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